Akèy › Kolit Ulseratif
Etid klinik pou Kolit Ulseratif ap rekrite nan Etazini
81 etid pou Kolit Ulseratif ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- New York City, NY24 etid
- Orlando, FL23 etid
- Miami, FL22 etid
- Houston, TX18 etid
- San Antonio, TX16 etid
- San Diego, CA16 etid
- Tacoma, WA15 etid
- Chicago, IL15 etid
- Colorado Springs, CO14 etid
- St. Louis, MO14 etid
- Tyler, TX14 etid
- Los Angeles, CA13 etid
- Washington, DC12 etid
- Boston, MA12 etid
- Cincinnati, OH11 etid
- Durham, NC11 etid
- Providence, RI11 etid
- Lewisville, TX10 etid
- Louisville, KY10 etid
- Parma, OH10 etid
- Tampa, FL10 etid
- Evanston, IL9 etid
- Atlanta, GA9 etid
- Lubbock, TX9 etid
- Mountain View, CA8 etid
- Cleveland, OH8 etid
- Lancaster, CA8 etid
- Seattle, WA8 etid
- Garland, TX8 etid
- Baltimore, MD8 etid
- Round Rock, TX8 etid
- Scottsdale, AZ8 etid
- Metairie, LA8 etid
- Memphis, TN8 etid
- Pittsburgh, PA7 etid
- Wyoming, MI7 etid
- Dallas, TX7 etid
- Dayton, OH7 etid
- Charlotte, NC7 etid
- Waukegan, IL7 etid
Pa eta
- Alabama7 etid
- Arizona19 etid
- Arkansas4 etid
- Colorado17 etid
- Connecticut11 etid
- Distrik Columbia3 etid
- Florid32 etid
- Georgia15 etid
- Idaho4 etid
- Illinois24 etid
- Indiana9 etid
- Iowa3 etid
- Kalifòni41 etid
- Kansas10 etid
- Kentucky13 etid
- Lwizyàn15 etid
- Maryland13 etid
- Massachusetts17 etid
- Michigan17 etid
- Minnesota8 etid
- Mississippi6 etid
- Missouri17 etid
- Nevada6 etid
- New Hampshire5 etid
- New Jersey7 etid
- New York31 etid
- North Carolina24 etid
- Ohio26 etid
- Oklahoma4 etid
- Oregon5 etid
- Pennsylvania13 etid
- Rhode Island11 etid
- South Carolina12 etid
- South Dakota4 etid
- Tennessee12 etid
- Texas34 etid
- Utah8 etid
- Virginia14 etid
- Washington22 etid
- Wisconsin4 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
Ap rekriteFaz 4
Laj 18 a 80 · Tout sèks · Mizajou Sep 30, 2026 · NCT06581328A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
Ap rekriteFaz 3
Laj 2 a 17 · Tout sèks · Mizajou Sep 30, 2026 · NCT07071519A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 30, 2026 · NCT06598943Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Ap rekriteEtid obsèvasyon
Laj 18 a 85 · Tout sèks · Mizajou Sep 30, 2026 · NCT07619547Confirmatory Clinical Study in Active Ulcerative Colitis
Ap rekriteFaz 2
Laj 16 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07296315A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 29, 2026 · NCT07012395A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 29, 2026 · NCT07845487Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
Ap rekriteFaz 1/2Volontè an sante akeyi
Laj 18 a 75 · Tout sèks · Mizajou Sep 29, 2026 · NCT06619990Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 29, 2026 · NCT07697456Immune Regulation in Ulcerative Colitis or Crohn s Disease
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
1 Day – 75 Years · Tout sèks · Mizajou Sep 28, 2026 · NCT00001184A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06979336A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 28, 2026 · NCT07463183A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
Ap rekriteFaz 3
Laj 12 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07196748A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Ap rekriteFaz 3
Laj 3 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06663332A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
Ap rekriteFaz 2/3
Laj 2 a 17 · Tout sèks · Mizajou Sep 24, 2026 · NCT05076175Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT06937086Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT03816345A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Sep 22, 2026 · NCT07483073LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Sep 22, 2026 · NCT07186101A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Ap rekriteFaz 3
Laj 2 a 19 · Tout sèks · Mizajou Sep 22, 2026 · NCT04844606LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Sep 22, 2026 · NCT07415044Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 21, 2026 · NCT07513181A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
Ap rekriteFaz 4
Laj 18 a 65 · Tout sèks · Mizajou Sep 21, 2026 · NCT06095128A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Sep 15, 2026 · NCT07185009Microbiome-targeted Diet Therapy in Ulcerative Colitis
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT07520461Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.